Ibrutinib plus rituximab and lenalidomide for primary intestinal diffuse large B-cell lymphoma relapsed after anti-CD19 CAR-T cell therapy: a case report

Ann Hematol. 2023 Dec;102(12):3625-3627. doi: 10.1007/s00277-023-05421-0. Epub 2023 Aug 22.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cell- and Tissue-Based Therapy
  • Humans
  • Lenalidomide / therapeutic use
  • Lymphoma, Large B-Cell, Diffuse* / drug therapy
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Neoplasm Recurrence, Local / drug therapy
  • Receptors, Chimeric Antigen*
  • Rituximab / therapeutic use

Substances

  • Rituximab
  • Lenalidomide
  • Receptors, Chimeric Antigen
  • ibrutinib